메뉴 건너뛰기




Volumn 7, Issue 29, 2016, Pages 46678-46691

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer

Author keywords

Angiogenesis; Antiangiogenic therapy; Bevacizumab; Hypoxia; Metastatic colorectal cancer

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CEDIRANIB; EVOFOSFAMIDE; FIRTECAN PEGOL; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB; SAPANISERTIB; TOPOTECAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HIF1A PROTEIN, HUMAN;

EID: 84979872943     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8712     Document Type: Review
Times cited : (32)

References (120)
  • 3
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539-1544.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson, A.B.8
  • 4
    • 84867047384 scopus 로고    scopus 로고
    • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30: 3499-3506.
    • (2012) J Clin Oncol , vol.30 , pp. 3499-3506
    • Van Cutsem, E.1    Tabernero, J.2    Lakomy, R.3    Prenen, H.4    Prausova, J.5    Macarulla, T.6    Ruff, P.7    van Hazel, G.A.8    Moiseyenko, V.9    Ferry, D.10    McKendrick, J.11    Polikoff, J.12    Tellier, A.13
  • 6
    • 84871879404 scopus 로고    scopus 로고
    • Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
    • Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012; 4: 301-319.
    • (2012) Ther Adv Med Oncol , vol.4 , pp. 301-319
    • Grothey, A.1    Allegra, C.2
  • 7
    • 20544455330 scopus 로고    scopus 로고
    • Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
    • Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005; 333: 328-335.
    • (2005) Biochem Biophys Res Commun , vol.333 , pp. 328-335
    • Ferrara, N.1    Hillan, K.J.2    Novotny, W.3
  • 8
    • 65349186800 scopus 로고    scopus 로고
    • Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
    • Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009; 9: 263-271.
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 263-271
    • Chu, Q.S.1
  • 9
    • 79954499886 scopus 로고    scopus 로고
    • Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    • Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129: 245-255.
    • (2011) Int J Cancer , vol.129 , pp. 245-255
    • Wilhelm, S.M.1    Dumas, J.2    Adnane, L.3    Lynch, M.4    Carter, C.A.5    Schutz, G.6    Thierauch, K.H.7    Zopf, D.8
  • 13
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-65.
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6    Griffing, S.7    Bergsland, E.8
  • 14
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
    • Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23: 3697-3705.
    • (2005) J Clin Oncol , vol.23 , pp. 3697-3705
    • Kabbinavar, F.F.1    Schulz, J.2    McCleod, M.3    Patel, T.4    Hamm, J.T.5    Hecht, J.R.6    Mass, R.7    Perrou, B.8    Nelson, B.9    Novotny, W.F.10
  • 16
    • 84884700039 scopus 로고    scopus 로고
    • Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    • Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14: 1077-1085.
    • (2013) Lancet Oncol , vol.14 , pp. 1077-1085
    • Cunningham, D.1    Lang, I.2    Marcuello, E.3    Lorusso, V.4    Ocvirk, J.5    Shin, D.B.6    Jonker, D.7    Osborne, S.8    Andre, N.9    Waterkamp, D.10    Saunders, M.P.11
  • 19
    • 84937204003 scopus 로고    scopus 로고
    • CALGB/ SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
    • Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O'Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky RL, et al. CALGB/ SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol. 2014; 25 (suppl 4).
    • (2014) Ann Oncol , vol.25
    • Lenz, H.1    Niedzwiecki, D.2    Innocenti, F.3    Blanke, C.4    Mahony, M.R.5    O'Neil, B.H.6    Shaw, J.E.7    Polite, B.8    Hochster, H.9    Atkins, J.10    Goldberg, R.11    Mayer, R.12    Schilsky, R.L.13
  • 20
    • 84929519878 scopus 로고    scopus 로고
    • Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials
    • Khattak MA, Martin H, Davidson A, Phillips M. Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. Clin Colorectal Cancer. 2015; 14:81-90.
    • (2015) Clin Colorectal Cancer , vol.14 , pp. 81-90
    • Khattak, M.A.1    Martin, H.2    Davidson, A.3    Phillips, M.4
  • 21
    • 84953856186 scopus 로고    scopus 로고
    • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    • Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16: 1306-1315.
    • (2015) Lancet Oncol , vol.16 , pp. 1306-1315
    • Cremolini, C.1    Loupakis, F.2    Antoniotti, C.3    Lupi, C.4    Sensi, E.5    Lonardi, S.6    Mezi, S.7    Tomasello, G.8    Ronzoni, M.9    Zaniboni, A.10    Tonini, G.11    Carlomagno, C.12    Allegrini, G.13
  • 25
    • 0022298591 scopus 로고
    • Proposal for using a standardized terminology on oxygen transport to tissue
    • Zander R, Vaupel P. Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol. 1985; 191: 965-970.
    • (1985) Adv Exp Med Biol , vol.191 , pp. 965-970
    • Zander, R.1    Vaupel, P.2
  • 26
    • 84923673640 scopus 로고    scopus 로고
    • The role of hypoxia in inflammatory disease (Review)
    • Biddlestone J, Bandarra D, Rocha S. The role of hypoxia in inflammatory disease (Review). Int J Mol Med. 2015; 35: 859-869.
    • (2015) Int J Mol Med , vol.35 , pp. 859-869
    • Biddlestone, J.1    Bandarra, D.2    Rocha, S.3
  • 27
    • 0035925098 scopus 로고    scopus 로고
    • Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects
    • Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93: 266-276.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 266-276
    • Hockel, M.1    Vaupel, P.2
  • 28
    • 0034989311 scopus 로고    scopus 로고
    • Biological consequences of tumor hypoxia
    • Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Sem Oncol. 2001; 28: 36-41.
    • (2001) Sem Oncol , vol.28 , pp. 36-41
    • Hockel, M.1    Vaupel, P.2
  • 29
  • 30
    • 0029051439 scopus 로고
    • Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension
    • Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92: 5510-5514.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 5510-5514
    • Wang, G.L.1    Jiang, B.H.2    Rue, E.A.3    Semenza, G.L.4
  • 33
    • 0025885693 scopus 로고
    • Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene
    • Pugh CW, Tan CC, Jones RW, Ratcliffe PJ. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci U S A. 1991; 88: 10553-10557.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 10553-10557
    • Pugh, C.W.1    Tan, C.C.2    Jones, R.W.3    Ratcliffe, P.J.4
  • 34
    • 0030460724 scopus 로고    scopus 로고
    • Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1
    • Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996; 271: 32529-32537.
    • (1996) J Biol Chem , vol.271 , pp. 32529-32537
    • Semenza, G.L.1    Jiang, B.H.2    Leung, S.W.3    Passantino, R.4    Concordet, J.P.5    Maire, P.6    Giallongo, A.7
  • 35
    • 60549083256 scopus 로고    scopus 로고
    • Regulation of cancer cell metabolism by hypoxia-inducible factor 1
    • Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Sem Cancer Biol. 2009; 19: 12-16.
    • (2009) Sem Cancer Biol , vol.19 , pp. 12-16
    • Semenza, G.L.1
  • 36
    • 84867514301 scopus 로고    scopus 로고
    • Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
    • Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18: 5585-5594.
    • (2012) Clin Cancer Res , vol.18 , pp. 5585-5594
    • Meijer, T.W.1    Kaanders, J.H.2    Span, P.N.3    Bussink, J.4
  • 37
    • 68749098573 scopus 로고
    • Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene
    • Algire GH, Chalkley HW, Earle WE, Legallais FY, Park HD, Shelton E, Schilling El. Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene. J Natl Cancer Inst. 1950; 11: 555-580.
    • (1950) J Natl Cancer Inst , vol.11 , pp. 555-580
    • Algire, G.H.1    Chalkley, H.W.2    Earle, W.E.3    Legallais, F.Y.4    Park, H.D.5    Shelton, E.6    Schilling, E.L.7
  • 38
    • 0023157363 scopus 로고
    • Angiogenic factors
    • Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987; 235: 442-447.
    • (1987) Science , vol.235 , pp. 442-447
    • Folkman, J.1    Klagsbrun, M.2
  • 39
    • 0031035987 scopus 로고    scopus 로고
    • Angiogenesis in colorectal cancer
    • Saclarides TJ. Angiogenesis in colorectal cancer. Surg Clin North Am. 1997; 77: 253-260.
    • (1997) Surg Clin North Am , vol.77 , pp. 253-260
    • Saclarides, T.J.1
  • 40
    • 0842333731 scopus 로고    scopus 로고
    • The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion
    • Takahashi Y, Ellis LM, Mai M. The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep. 2003; 10: 9-13.
    • (2003) Oncol Rep , vol.10 , pp. 9-13
    • Takahashi, Y.1    Ellis, L.M.2    Mai, M.3
  • 42
    • 85013312416 scopus 로고
    • Tumor angiogenesis: therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 43
    • 0037967272 scopus 로고    scopus 로고
    • Tumorigenesis and the angiogenic switch
    • Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-410.
    • (2003) Nat Rev Cancer , vol.3 , pp. 401-410
    • Bergers, G.1    Benjamin, L.E.2
  • 46
    • 33751192872 scopus 로고    scopus 로고
    • Regulation of angiogenesis by hypoxia and hypoxia-inducible factors
    • Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006; 76: 217-257.
    • (2006) Curr Top Dev Biol , vol.76 , pp. 217-257
    • Hickey, M.M.1    Simon, M.C.2
  • 47
    • 0036842215 scopus 로고    scopus 로고
    • Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    • Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20: 4368-4380.
    • (2002) J Clin Oncol , vol.20 , pp. 4368-4380
    • Dvorak, H.F.1
  • 48
    • 47949089077 scopus 로고    scopus 로고
    • VEGF-targeted therapy: mechanisms of anti-tumour activity
    • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-591.
    • (2008) Nat Rev Cancer , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 49
    • 0030026897 scopus 로고    scopus 로고
    • A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
    • Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15: 290-298.
    • (1996) EMBO J , vol.15 , pp. 290-298
    • Joukov, V.1    Pajusola, K.2    Kaipainen, A.3    Chilov, D.4    Lahtinen, I.5    Kukk, E.6    Saksela, O.7    Kalkkinen, N.8    Alitalo, K.9
  • 50
    • 0032549799 scopus 로고    scopus 로고
    • Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
    • Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92: 735-745.
    • (1998) Cell , vol.92 , pp. 735-745
    • Soker, S.1    Takashima, S.2    Miao, H.Q.3    Neufeld, G.4    Klagsbrun, M.5
  • 51
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 52
    • 0033118228 scopus 로고    scopus 로고
    • VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
    • Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999; 18: 2221-2230.
    • (1999) Oncogene , vol.18 , pp. 2221-2230
    • Takahashi, T.1    Ueno, H.2    Shibuya, M.3
  • 53
    • 0035966004 scopus 로고    scopus 로고
    • Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation
    • Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem. 2001; 276: 49289-49298.
    • (2001) J Biol Chem , vol.276 , pp. 49289-49298
    • Meadows, K.N.1    Bryant, P.2    Pumiglia, K.3
  • 55
    • 21144437844 scopus 로고    scopus 로고
    • Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels
    • He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65: 4739-4746.
    • (2005) Cancer Res , vol.65 , pp. 4739-4746
    • He, Y.1    Rajantie, I.2    Pajusola, K.3    Jeltsch, M.4    Holopainen, T.5    Yla-Herttuala, S.6    Harding, T.7    Jooss, K.8    Takahashi, T.9    Alitalo, K.10
  • 56
    • 0037093078 scopus 로고    scopus 로고
    • Placental growth factor is a survival factor for tumor endothelial cells and macrophages
    • Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 2002; 62: 2749-2752.
    • (2002) Cancer Res , vol.62 , pp. 2749-2752
    • Adini, A.1    Kornaga, T.2    Firoozbakht, F.3    Benjamin, L.E.4
  • 57
    • 84867235528 scopus 로고    scopus 로고
    • Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
    • 63-8722-5-63
    • Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012; 5: 63-8722-5-63.
    • (2012) J Hematol Oncol , vol.5
    • Sun, W.1
  • 60
    • 67650753834 scopus 로고    scopus 로고
    • The role of the Angiopoietins in vascular morphogenesis
    • Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009; 12: 125-137.
    • (2009) Angiogenesis , vol.12 , pp. 125-137
    • Thomas, M.1    Augustin, H.G.2
  • 61
    • 54549089738 scopus 로고    scopus 로고
    • Hypoxia signalling through mTOR and the unfolded protein response in cancer
    • Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008; 8: 851-864.
    • (2008) Nat Rev Cancer , vol.8 , pp. 851-864
    • Wouters, B.G.1    Koritzinsky, M.2
  • 62
    • 28844470269 scopus 로고    scopus 로고
    • The unfolded protein response: a novel component of the hypoxic stress response in tumors
    • Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res. 2005; 3: 597-605.
    • (2005) Mol Cancer Res , vol.3 , pp. 597-605
    • Feldman, D.E.1    Chauhan, V.2    Koong, A.C.3
  • 63
    • 33746886623 scopus 로고    scopus 로고
    • "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPRindependent pathways
    • Koumenis C, Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPRindependent pathways. Mol Cancer Res. 2006; 4: 423-436.
    • (2006) Mol Cancer Res , vol.4 , pp. 423-436
    • Koumenis, C.1    Wouters, B.G.2
  • 64
    • 67349119514 scopus 로고    scopus 로고
    • Regulation of angiogenesis by oxygen sensing mechanisms
    • Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med. 2009; 87: 549-560.
    • (2009) J Mol Med , vol.87 , pp. 549-560
    • Fong, G.H.1
  • 65
    • 0029551759 scopus 로고
    • Microvascular corrosion casting in the study of tumor vascularity: a review
    • discussion 1243-1244
    • Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scan Micr. 1995; 9: 1233-1243; discussion 1243-1244.
    • (1995) Scan Micr , vol.9 , pp. 1233-1243
    • Konerding, M.A.1    Miodonski, A.J.2    Lametschwandtner, A.3
  • 66
    • 84912096468 scopus 로고    scopus 로고
    • Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia
    • Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014; 26: 605-622.
    • (2014) Cancer Cell , vol.26 , pp. 605-622
    • Jain, R.K.1
  • 68
    • 77951228314 scopus 로고    scopus 로고
    • The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy
    • DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci. 2010; 15: 213-225.
    • (2010) Front Biosci , vol.15 , pp. 213-225
    • DeClerck, K.1    Elble, R.C.2
  • 69
    • 0035432151 scopus 로고    scopus 로고
    • Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review)
    • Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol. 2001; 19: 257-262.
    • (2001) Int J Oncol , vol.19 , pp. 257-262
    • Blagosklonny, M.V.1
  • 70
    • 1642472018 scopus 로고    scopus 로고
    • Antiangiogenic therapy and tumor progression
    • Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5: 13-17.
    • (2004) Cancer Cell , vol.5 , pp. 13-17
    • Blagosklonny, M.V.1
  • 71
    • 84922977686 scopus 로고    scopus 로고
    • Regulatory role of glycans in the control of hypoxiadriven angiogenesis and sensitivity to anti-angiogenic treatment
    • Croci DO, Cerliani JP, Pinto NA, Morosi LG, Rabinovich GA. Regulatory role of glycans in the control of hypoxiadriven angiogenesis and sensitivity to anti-angiogenic treatment. Glycobiology. 2014; 24: 1283-1290.
    • (2014) Glycobiology , vol.24 , pp. 1283-1290
    • Croci, D.O.1    Cerliani, J.P.2    Pinto, N.A.3    Morosi, L.G.4    Rabinovich, G.A.5
  • 73
    • 84914105725 scopus 로고    scopus 로고
    • Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy
    • Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Met Rev. 2014; 33: 1095-1108.
    • (2014) Cancer Met Rev , vol.33 , pp. 1095-1108
    • Fais, S.1    Venturi, G.2    Gatenby, B.3
  • 75
    • 84899771418 scopus 로고    scopus 로고
    • Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells
    • McDonald PC, Dedhar S. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem. 2014; 75: 255-269.
    • (2014) Subcell Biochem , vol.75 , pp. 255-269
    • McDonald, P.C.1    Dedhar, S.2
  • 76
    • 79956196320 scopus 로고    scopus 로고
    • Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis
    • Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011; 711: 167-173.
    • (2011) Mutat Res , vol.711 , pp. 167-173
    • Ziech, D.1    Franco, R.2    Pappa, A.3    Panayiotidis, M.I.4
  • 77
    • 84881232071 scopus 로고    scopus 로고
    • Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
    • Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013; 123: 3190-3200.
    • (2013) J Clin Invest , vol.123 , pp. 3190-3200
    • Welti, J.1    Loges, S.2    Dimmeler, S.3    Carmeliet, P.4
  • 81
    • 77954563464 scopus 로고    scopus 로고
    • Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
    • Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Met Rev. 2010; 29: 285-293.
    • (2010) Cancer Met Rev , vol.29 , pp. 285-293
    • Finger, E.C.1    Giaccia, A.J.2
  • 82
    • 84858590826 scopus 로고    scopus 로고
    • Accessories to the crime: functions of cells recruited to the tumor microenvironment
    • Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21: 309-322.
    • (2012) Cancer Cell , vol.21 , pp. 309-322
    • Hanahan, D.1    Coussens, L.M.2
  • 83
    • 84880757177 scopus 로고    scopus 로고
    • Deciphering and reversing tumor immune suppression
    • Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013; 39: 61-73.
    • (2013) Immunity , vol.39 , pp. 61-73
    • Motz, G.T.1    Coukos, G.2
  • 84
    • 84904406680 scopus 로고    scopus 로고
    • Tumor-associated macrophages: from mechanisms to therapy
    • Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41: 49-61.
    • (2014) Immunity , vol.41 , pp. 49-61
    • Noy, R.1    Pollard, J.W.2
  • 86
    • 84899753178 scopus 로고    scopus 로고
    • PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
    • Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211: 781-790.
    • (2014) J Exp Med , vol.211 , pp. 781-790
    • Noman, M.Z.1    Desantis, G.2    Janji, B.3    Hasmim, M.4    Karray, S.5    Dessen, P.6    Bronte, V.7    Chouaib, S.8
  • 87
    • 79957534572 scopus 로고    scopus 로고
    • Targeting hypoxia in cancer therapy
    • Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11: 393-410.
    • (2011) Nat Rev Cancer , vol.11 , pp. 393-410
    • Wilson, W.R.1    Hay, M.P.2
  • 90
    • 84904987878 scopus 로고    scopus 로고
    • Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
    • Mesange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A, Larsen AK. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget. 2014; 5: 4709-4721. doi: 10.18632/oncotarget.1671.
    • (2014) Oncotarget , vol.5 , pp. 4709-4721
    • Mesange, P.1    Poindessous, V.2    Sabbah, M.3    Escargueil, A.E.4    de Gramont, A.5    Larsen, A.K.6
  • 91
    • 84947748945 scopus 로고    scopus 로고
    • Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
    • Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget. 2015; 6: 38166-38180. doi: 10.18632/oncotarget.6241.
    • (2015) Oncotarget , vol.6 , pp. 38166-38180
    • Greening, D.W.1    Lee, S.T.2    Ji, H.3    Simpson, R.J.4    Rigopoulos, A.5    Murone, C.6    Fang, C.7    Gong, S.8    O'Keefe, G.9    Scott, A.M.10
  • 96
    • 84856302564 scopus 로고    scopus 로고
    • Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study
    • Hattingen E, Jurcoane A, Bahr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 2011; 13: 1349-1363.
    • (2011) Neuro Oncol , vol.13 , pp. 1349-1363
    • Hattingen, E.1    Jurcoane, A.2    Bahr, O.3    Rieger, J.4    Magerkurth, J.5    Anti, S.6    Steinbach, J.P.7    Pilatus, U.8
  • 103
    • 0036359548 scopus 로고    scopus 로고
    • Hypoxia-a key regulatory factor in tumour growth
    • Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
    • (2002) Nat Rev Cancer , vol.2 , pp. 38-47
    • Harris, A.L.1
  • 105
    • 0034909448 scopus 로고    scopus 로고
    • Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer
    • Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol. 2001; 24: 376-378.
    • (2001) Am J Clin Oncol , vol.24 , pp. 376-378
    • Tas, F.1    Aydiner, A.2    Demir, C.3    Topuz, E.4
  • 106
    • 0035205830 scopus 로고    scopus 로고
    • Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease
    • Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001; 24: 547-550.
    • (2001) Am J Clin Oncol , vol.24 , pp. 547-550
    • Tas, F.1    Aykan, F.2    Alici, S.3    Kaytan, E.4    Aydiner, A.5    Topuz, E.6
  • 108
    • 84907376447 scopus 로고    scopus 로고
    • Initial LDH level can predict the survival benefit from bevacizumab in the firstline setting in Chinese patients with metastatic colorectal cancer
    • Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the firstline setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014; 7: 1415-1422.
    • (2014) Onco Targets Ther , vol.7 , pp. 1415-1422
    • Yin, C.1    Jiang, C.2    Liao, F.3    Rong, Y.4    Cai, X.5    Guo, G.6    Qiu, H.7    Chen, X.8    Zhang, B.9    He, W.10    Xia, L.11
  • 110
    • 84895073003 scopus 로고    scopus 로고
    • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study
    • Bar J, Spencer S, Morgan S, Brooks L, Cunningham D, Robertson J, Jurgensmeier JM, Goss GD. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study. Clin Colorectal Cancer. 2014; 13: 46-53.
    • (2014) Clin Colorectal Cancer , vol.13 , pp. 46-53
    • Bar, J.1    Spencer, S.2    Morgan, S.3    Brooks, L.4    Cunningham, D.5    Robertson, J.6    Jurgensmeier, J.M.7    Goss, G.D.8
  • 111
    • 84979949771 scopus 로고    scopus 로고
    • HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer
    • January 20 Supplement
    • Marisi G, Ulivi P, Scarpi E, Passardi A, Frassineti GL, Valgiusti M, Zoli W, Amadori D. HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer. J Clin Oncol. 2015; 33 No 3_suppl (January 20 Supplement): 601.
    • (2015) J Clin Oncol , vol.33 , Issue.3 , pp. 601
    • Marisi, G.1    Ulivi, P.2    Scarpi, E.3    Passardi, A.4    Frassineti, G.L.5    Valgiusti, M.6    Zoli, W.7    Amadori, D.8
  • 114
    • 1242271198 scopus 로고    scopus 로고
    • Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications
    • Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64: 1475-1482.
    • (2004) Cancer Res , vol.64 , pp. 1475-1482
    • Rapisarda, A.1    Uranchimeg, B.2    Sordet, O.3    Pommier, Y.4    Shoemaker, R.H.5    Melillo, G.6
  • 117
    • 84894523716 scopus 로고    scopus 로고
    • Making new contacts: the mTOR network in metabolism and signalling crosstalk
    • Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Biol. 2014; 15: 155-162.
    • (2014) Nat Rev Mol Biol , vol.15 , pp. 155-162
    • Shimobayashi, M.1    Hall, M.N.2
  • 119
    • 84958963072 scopus 로고    scopus 로고
    • Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1alpha and Induces Apoptosis in Human Colorectal Cancer Cells
    • Bach DH, Kim SH, Hong JY, Park HJ, Oh DC, Lee SK. Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1alpha and Induces Apoptosis in Human Colorectal Cancer Cells. Mar Drugs. 2015; 13: 6962-6976.
    • (2015) Mar Drugs , vol.13 , pp. 6962-6976
    • Bach, D.H.1    Kim, S.H.2    Hong, J.Y.3    Park, H.J.4    Oh, D.C.5    Lee, S.K.6
  • 120
    • 31144458716 scopus 로고    scopus 로고
    • How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy
    • Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther. 2005; 4: 1307-1310.
    • (2005) Cancer Biol Ther , vol.4 , pp. 1307-1310
    • Blagosklonny, M.V.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.